Raphael Pharmaceutical INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
OQB
Raphael Pharmaceutical Inc. Chief Technology Officer, Hayon Igal Louria, exercised warrants to acquire 350,000 shares of common stock.
OQB
Director Yehuda Eliya reports the expiration of 202,000 warrants and receipt of 200,000 new warrants in Raphael Pharmaceuticals.
OQB
Raphael Pharmaceuticals CEO Shlomo Pilo reports acquiring 200,000 shares of common stock and warrants to purchase 100,000 shares at $0.50 per share and warrant.
OQB
Form 4: Raphael Pharmaceuticals Director Ajay Kumar Dhadha Acquires Shares and Warrants as Compensation
Director Ajay Kumar Dhadha receives 350,000 shares of common stock and warrants for 250,000 shares as compensation for his service as a director and chairman of Raphael Pharmaceuticals.
OQB
Form 4: Raphael Pharmaceutical Inc. Director Eliya Yehuda Reports Acquisition and Disposal of Common Stock
Director Eliya Yehuda reports acquiring 150,000 shares of Raphael Pharmaceutical Inc. common stock at $0.40 per share and disposing of 352,000 shares.
OQB
Igal Louria Hayon, Chief Technology Officer of Raphael Pharmaceutical Inc., exercised warrants to purchase 999,000 shares of common stock at $0.01 per share on August 29, 2023.